Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535361 · ClinicalTrials.gov registry record · NA
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome
A NA study of Short Bowel Syndrome, sponsored by Eclipse Regenesis.
- Recruiting
- Registry status
- NA
- Development phase
- 40
- Enrollment target
- 6
- Study locations
NCT05535361 is a NA study of Short Bowel Syndrome that is actively recruiting participants, run by Eclipse Regenesis. The registered enrollment target is 40 participants, below the 182-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (78% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT05535361, a NA study of Short Bowel Syndrome, is actively recruiting participants, sponsored by Eclipse Regenesis.
- RECRUITING
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
- 6
- Study locations
Study Summary
A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome
Conditions Studied
Interventions
- DEVICE Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome
Study Locations (6)
California
- Lucile Packard Children's Hospital Stanford - Palo Alto
- University of California San Francisco - San Francisco
- Stanford University School of Medicine - Stanford
District of Columbia
- Children's National Hospital - Washington D.C.
Massachusetts
- Boston Children's Hospital - Boston
Ohio
- Cincinnati Children's Hospital - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-09-15 |
| Est. Completion | 2028-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05535361
The ClinicalTrials.gov registry entry for NCT05535361 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 17 other Short Bowel Syndrome trials with a reported enrollment target (78% lower). The listed sponsor is Eclipse Regenesis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Short Bowel Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome is the first listed.
NCT05535361 reports 6 study locations spanning 4 distinct geographic areas - top geographies include California, District of Columbia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05535361 about?
NCT05535361 is a clinical study titled "A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients With Short Bowel Syndrome". A Feasibility Study to Evaluate Safety and Probable Benefit of the Eclipse XL1 System for Distraction Enterogenesis in Adult and Pediatric Patients with Short Bowel Syndrome
What is the current status of trial NCT05535361?
This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-09-15. Estimated completion is 2028-06-30.
What conditions does trial NCT05535361 study?
This clinical trial studies the following conditions: Short Bowel Syndrome.
What interventions are being tested in trial NCT05535361?
The interventions under investigation include: Distraction Enterogenesis in Adult Patients with Short Bowel Syndrome (DEVICE).
Who is sponsoring clinical trial NCT05535361?
This trial is sponsored by Eclipse Regenesis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05535361 being conducted?
This trial has 6 study locations across California, District of Columbia, Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Short Bowel Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A 90 Day, Phase 3,Open Labeled Exploratory Study of RELiZORB
RECRUITING · NA
-
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
RECRUITING · Early Phase 1
-
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
RECRUITING · Phase 2
-
Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS
RECRUITING · Phase 3
-
Registry for Participants With Short Bowel Syndrome
ACTIVE NOT RECRUITING
-
Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.